BMRN250117C130000
- 0.30
- 0.000.00%
Biomarin Pharmaceutical Newsroom
Jefferies Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $110
Jefferies Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $110
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $105 to $127
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $81 to $122
BioMarin Pharmaceutical's Promising Growth and Strategic Outlook Justifies Buy Rating
Bernstein Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $90
Bernstein Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Biomarin Pharmaceutical Analyst Ratings
BofA Securities Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $101
J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
Jefferies Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $122
Jefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research
Biomarin Pharmaceutical Analyst Ratings
Wolfe Research Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $95
Wedbush Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $94
Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $86
Oppenheimer Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating